Alzheimer's Drug Trial Seeks Participants

Alzheimer's Drug Trial Seeks Participants

Feb 19, 2009 9:43 AM

SALT LAKE CITY -- The Center for Alzheimer's Care, Imaging and Research at the University of Utah is seeking patients in the trial of an experimental medication to block nerve damage and inflammation in the brain that can lead to progressive memory loss and behavioral changes in people with Alzheimer's disease.

The U center is one of 40 across the nation looking for a total of 400 patients with mild to moderate Alzheimer's disease for the trial. Edward Y. Zamrini, M.D., associate professor of neurology at the U School of Medicine and clinical trials director at the Center for Alzheimer's Care, Imaging and Research, is leading the Utah portion of the study. He hopes to recruit at least 10 patients, age 50 and older, locally.

"In addition to monitoring disease progression through cognitive tests, we will examine various biological markers of the disease," Zamrini said. "These include the degree of atrophy (or shrinkage) of the brain as measured by magnetic resonance imaging (MRI), the extent of amyloid buildup in the brain assessed by Positron Emission Tomography (PET) imaging, and levels of amyloid beta and other proteins in blood and spinal fluid."

Plaque buildup can trigger inflammation in the brains of people with Alzheimer's disease. A protein called amyloid beta builds up in plaque deposits and may promote damage to nerve cells.  Current Alzheimer's disease therapies focus on improving symptoms versus attacking the root of the disease progression. The trial will test an experimental drug that seeks to stop amyloid beta from binding to a receptor in the brain called RAGE (receptor for advanced glycation endproducts). The drug, which has been tested in animals and in preliminary human studies, is being studied in this Phase II clinical trial to determine if it will slow the progressive decline associated with Alzheimer's disease.

Physicians and nurses will monitor the participants during regular visits and measure the severity and progression of disease using standard tests of functional and cognitive abilities. To ensure unbiased results, neither the researchers conducting the trial nor the participants will know who is receiving the study drug and who is getting the placebo.

The industry-sponsored study is being conducted by the Alzheimer's Disease Cooperative Study (ADCS), a consortium of leading researchers supported by the National Institute on Aging (NIA), part of National Institutes of Health (NIH).  The ADCS at the University of California, San Diego (UCSD), will coordinate the 18-month, double-blind, placebo-controlled clinical trial. 

Douglas Galasko, M.D., professor of neurology at UCSD, is directing the study nationally.  "The evidence from basic research studies is compelling and merits further evaluation in a rigorous human clinical trial," Galasko said. "While most current Alzheimer's disease therapies focus on the various symptoms of cognitive impairment, this trial is testing whether we can modify actual progression of the disease itself by targeting the interaction between amyloid beta and an important receptor in the brain."

The ADCS consortium is a public resource, supported by the NIA, to facilitate the study of potential new therapies for Alzheimer's disease. Its nationwide outreach is critical to the recruitment of participants into such studies. "Progress in treating and preventing Alzheimer's would just not be possible without the dedication of the patients and families who volunteer for clinical trials," said Neil Buckholtz, Ph.D., chief of the NIA Dementias of Aging Branch.

Much of the pre-clinical, basic research connecting RAGE to amyloid beta that led to the current study was performed by scientists at Columbia University, the University of Perugia in Italy, and the University of Magdeburg in Germany.

People interested in joining the trial can contact the study line at (801) 587-7888. The Center for Alzheimer' Care, Imaging and Research also encourages those interested in its memory-related research to register online at Click on the "Join Our Research" link to the left.           

To view a list of the research sites or for information on dementia and aging, go to

# # #

Media Contacts

Phil Sahm
Office of Public Affairs
Phone: (801) 581-2517

Visit our News Archive for a complete list of previous News.